BioCatalystWatch
FATEWorkspace / FATE / OverviewCompany library
FATE THERAPEUTICS INC logo

FATE THERAPEUTICS INC

FATE THERAPEUTICS INC (FATE)

Website

Featured programme · ProHema

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

FT819

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

FT836

MICA/B × 4-1BB

FT839

CD19 × CD38

PreINDP1P3FilingApproved
Upcoming / outlook

FT839

CD19 × CD38

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

FT839

CD19 × CD38

PreINDP1P3FilingApproved
Upcoming / outlook

FT819

CD19

PreINDP1P2P3FilingApproved
Upcoming / outlook

FT836

MICA/B × 4-1BB

FT839

CD19 × CD38

Other pipelines

FT819

CD19

PreINDP1P2P3FilingApproved

FT836

MICA/B × 4-1BB

PreINDP1P2P3FilingApproved
FT839

CD19 × CD38

FT839

CD19 / CD38

IND

PreINDP1P2P3FilingApproved
FT839

CD19 / CD38

IND

PreINDP1P2P3FilingApproved
FT839

CD19 / CD38

IND

PreINDP1P2P3FilingApproved
FT839

CD19 / CD38

IND

PreINDP1P2P3FilingApproved
FT839

CD19 / CD38

IND

PreINDP1P2P3FilingApproved
FT839

FT522

CD19 × 4-1BB (CD137)

PreINDP1P2P3FilingApproved
FT522

CD19 × 4-1BB (CD137)

PreINDP1P2P3FilingApproved
ProHema

PreINDP1P2P3FilingApproved

History / paused

FT819

CD19

PreINDP1P2P3FilingApproved

CD19

PreINDP1P2P3FilingApproved

CD19

PreINDP2P3FilingApproved

CD19

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

FATE PR & News

PR & News

FATE SEC archive